Skip to main content

Table 3 Laboratory data for 124 patients with type 2 diabetes according to progression of diabetic nephropathy

From: Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes

 

Stage 1

Stage 2

Stage 3

Stage 4

P value

Subjects (male/female)

59(42/17)

40(24/16)

19(17/2)

6(5/1)

 

Serum creatinine (mg/dl)

0.73±0.02

0.81±0.03

0.87±0.03*

1.2±0.10**,##,$$

< 0.001

eGFR (ml/min)

80.1±2.6

69.3±2.9*

68.7±4.0

46.5±3.2**,#

<0.001

Albuminuria (mg/g creatinine)

12.4±1.1

95.0±10.7**

483.8±63.6**,##

538.0±98.4**,##

<0.001

Serum osteoprotegerin (pg/ml)

183.8±117.5

329.6±227.4

168.1±87.2

59.8±27.6

0.876

Serum osteocalcin (ng/ml)

1.58±0.21

1.79±0.26

1.35 ±0.32

2.06 ±0.76

0.696

Serum 25-hydroxyvitamin D3 (nmol/l)

85.3±5.71

86.2±6.52

103.3±14.9

81.1±18.8

0.516

Serum FGF23 (pg/ml)

32.6±1.83

33.2±3.53

36.1±3.57

58.7±7.08**

0.007

No calcification, n

41

26

13

5

 

Calcification, n

18

14

4

1

 
  1. Values are shown as mean ± SE and were analyzed by ANOVA. * P < 0.05 vs. 1st quartile. ** P < 0.01 vs. 1st quartile. # P < 0.05 vs. 2nd quartile. ## P < 0.01 vs. 2nd quartile. $ P < 0.05 vs. 3rd quartile. $$ P < 0.01 vs. 3rd quartile.